


FIG. 1

**Binding affinity of huMOV19-14
vs huMOV19 antibody on T47D cells**



	huMOV19-14	huMOV19
EC50	3.793e-010	1.438e-010

FIG. 2




FIG. 3




FIG. 4A





FIG. 4B





FIG. 4C




FIG. 5A

Effect of 0, 500, 1000, 2000, and 4000 Kara (CD33+) cells on 500 RADA-1 (CD33-) cells in the presence of 1.0e-9M huMy9-6-14 conjugate




FIG. 5B

Effect of 0, 500, 1000, 2000, and 4000 Kara (CD33+) cells on 500
RADA-1 (CD33-) cells in the presence of 5.0×10^{-10} M huMy9-6-14
conjugates





FIG. 6

Anti-Tumor Activity (Median Tumor Volume, mm³) of huMOV19-80 and huMOV19-90 in SCID Mice Bearing NCI-H2110 Xenografts



Treatment Group		Dose (ug/kg)	T/C (Day 23)	Regressions		Result
				PR	CR	
A	Control	-	-	-	-	-
B	huMOV19-80	5	47%	0/6	0/6	Inactive
C	huMOV19-80	25	5%	5/6	1/6	Highly Active
D	huMOV19-90	5	0%	6/6	6/6	Highly Active
E	huMOV19-90	25	0%	6/6	6/6	Highly Active

FIG. 7A




MS for deglycosylated huMov19-14 Conjugate**MS for deglycosylated huMov19-sulfo-SPDB-98 Conjugate****MS for deglycosylated huMov19-35 Conjugate**

FIG. 7B




MS for deglycosylated huMov19-63 Conjugate**MS for deglycosylated huMov19-80 Conjugate****MS for deglycosylated huMOV19-90 Conjugate**

FIG. 7C




MS for deglycosylated huMov19-49 ConjugateMS for deglycosylated huMov19-sulfo-SPDB-99 ConjugateMS for deglycosylated huMov19-70 Conjugate

FIG. 7D


MS for deglycosylated huMov19-23 Conjugate

FIG. 8


MS for deglycosylated huML66-90 Conjugate

FIG. 9




FIG. 10

Potency of huMOV19-90 conjugate on KB cells

-/+ 1 μ M huMOV19 antibody blocking
1000 cells/ well, 5 day continuous, 2 hr WST-8




FIG. 11

Potency of huMOV19-90 on NCI-H2110 cells

-/+ 1 μ M huMOV19 blocking antibody
2000 cells/ well, 5 day continuous, 3 hr WST-8




FIG. 12




FIG. 13





FIG. 14

Anti-Tumor Activity (Median Tumor Volume, mm³) of huMov19-90 in SCID Mice Bearing NCI-H2110 Xenografts




Treatment Group		Compound Dose (µg/kg)	T/C (Day 28)	Regressions		Result
				PR	CR	
A	Control	-	-	-	-	-
B	huMov19-90	1	107%	0/6	0/6	Inactive
C	huMov19-90	3	14%	1/6	0/6	Active
D	huMov19-90	5	1%	6/6	3/6	Highly Active

FIG. 15

FIG. 15A

Binding of huMOV19-90 conjugate on T47D cells



	huMOV19-90	huMOV19
EC50	3.708e-010	3.136e-010

FIG. 15B




FIG. 16



MS for deglycosylated huMov19-sulfo-SPDB-107 Conjugate

FIG. 17

Anti-Tumor Activity (Median Tumor Volume, mm³) of huML66-90 conjugate in SCID Mice Bearing NCI-H1703 Xenografts



Agent	Compound 90 dose (µg/kg)	Ab dose (mg/kg)	T/C (%)	CR	Results
huML66-90 conjugate	5	0.3	46	0/6	inactive
	20	1.1	4	3/6	highly active
	50	2.8	0	6/6	highly active

FIG. 18

Pharmacokinetics of huMov19-90 in CD-1 mice




FIG. 19A




FIG. 19B




FIG. 20




FIG. 21

FIG. 21A Ishikawa cells




FIG. 21B KB cells




FIG. 21C NCI-H2110 cells






FIG. 22




Treatment Group		Dose (µg/kg)	T/C (Day 24)	Regressions		Result
				PR	CR	
A	Vehicle Control	—	—	—	—	—
B	huMov19-90	1	117%	0/6	0/6	Inactive
C	huMov19-90	3	13%	1/6	0/6	Active
D	huMov19-90	5	2%	6/6	4/6	Highly Active

FIG. 23




Treatment Group		Dose (µg/kg)	T/C (Day 33)	Regressions		Result
				PR	CR	
A	Vehicle Control	-	-	-	-	-
B	huMov19-90	10	15%	1/6	0/6	Active
C	huMov19-90	30	9%	6/6	6/6	Highly Active
D	chKTI-90	30	34%	0/6	0/6	Active

FIG. 24



Treatment Group		Dose (µg/kg)	T/C (Day 32)	Regressions		Result
				PR	CR	
A	Vehicle Control	-	-	-	-	-
E	huMov19-90	10	27%	6/6	6/6	Active
F	huMov19-90	30	15%	6/6	6/6	Active
G	chKTI-90	30	24%	4/6	0/6	Active

FIG. 25



Treatment Group		Dose (µg/kg)	T/C (Day 28)	Regressions		Result
				PR	CR	
A	Vehicle Control	-	-	-	-	-
B	huMov19-107	1	102%	0/6	0/6	Inactive
C	huMov19-107	3	60%	1/6	1/6	Inactive
D	huMov19-107	10	0%	6/6	6/6	Highly Active
E	chKTI-107	10	89%	0/6	0/6	Inactive

FIG. 26

